3,883
edits
Changes
Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations (view source)
Revision as of 16:42, 22 April 2021
, 16:42, 22 April 2021Jennelleh moved page TestPCDtable to Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations without leaving a redirect
'''Table 1 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
'''Table 1 - Clinically significant cytogenomic alterations in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. See Table 2 for references and Level 3 evidence. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Evidence Level'''
|'''Evidence Level'''
| rowspan="11" |'''Level 1'''
| rowspan="11" |'''Level 1'''
well established evidence in NCCN guideline, WHO criteria, FDA-approved, COG recommendation, or based on large body of publications.
well established evidence in NCCN guideline,
WHO criteria, FDA-approved, COG
recommendation, or based on large body of publications.
|Hyperdiploidy (+3, +5, +7, +9, +11, +15, +21)
|Hyperdiploidy (+3, +5, +7, +9, +11, +15, +21)
|Good prognosis
|Good prognosis
|t(4;14)
|t(4;14)
|Poor prognosis, predicts bortezomib response
|Poor prognosis, predicts bortezomib response
|''IGH''
|''[[IGH]]''
|-
|-
|t(6;14)
|t(6;14)
|Good prognosis
|Good prognosis
|''IGH''
|''[[IGH]]''
|-
|-
|t(14;16)
|t(14;16)
|Poor prognosis
|Poor prognosis
|''IGH''
|''[[IGH]]''
|-
|-
|t(11;14)
|t(11;14)
|Good prognosis
|Good prognosis
|''IGH''
|''[[IGH]]''
|-
|-
|t(14;20)
|t(14;20)
|8q24.2+
|8q24.2+
|Recurrent
|Recurrent
|''MYC''
|''[[MYC]]''
|-
|-
|9p+
|9p+
|del(10q23.31)
|del(10q23.31)
|Recurrent
|Recurrent
|''PTEN''
|''[[PTEN]]''
|-
|-
|11q+
|11q+
|del(13q32.2)
|del(13q32.2)
|Recurrent
|Recurrent
|''TGDS''
|''[[TGDS]]''
|-
|-
|del(14q)
|del(14q)
|22q21+
|22q21+
|Associated with relapse
|Associated with relapse
|''PRAME''
|''[[PRAME]]''
|-
|-
|del(X), X+, X CN-LOH
|del(X), X+, X CN-LOH
|
|
|}
|}
'''Table 1 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
'''Table 2 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Chromosome'''
|'''Chromosome'''
| 17p13
| 17p13
|Loss
|Loss
|''[[ATP1B2]], '''[[TP53]]''', [[WRAP5]], [[EFNB3]]''
|''[[ATP1B2]], [[TP53]], [[WRAP5]], [[EFNB3]]''
| Predictive & prognostic
| Predictive & prognostic
|1
|1